Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis

Tissue Antigens

Volumn 70, Issue 4, 2007, Pages 294-300

  Lawless, M W ^a   White, M ^a   Mankan, A K ^a   O'Dwyer, M J ^a   Norris, S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Hereditary hemochromatosis; HFE; Inflammation; Monocyte chemoattractant protein 1; Serum iron indexes

Indexed keywords

FERRITIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFERRIN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEMOCHROMATOSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CHEMOKINE CCL2; FEMALE; FERRITINS; HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; TRANSFERRIN;

EID: 34548348137     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00895.x     Document Type: Article

References (47)

1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003 : 3 : 783 8.
2. Loreal O, Brissot P. Hepcidin: the grail of iron metabolism. Gastroenterol Clin Biol 2002 : 8-9 : 805 7.
3. Deicher R, Horl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006 : 5 : 301 9.
4. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005 : 6 : 1906 10.
5. Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide- induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A 2004 : 25 : 9263 5.
6. Constante M, Jiang W, Wang D, Raymond VA, Bilodeau M, Santos MM. Distinct requirements for Hfe in basal and induced hepcidin levels in iron overload and inflammation. Am J Physiol Gastrointest Liver Physiol 2006 : 2 : 229 37.
7. Rollins BJ. Chemokines. Blood 1997 : 3 : 909 28.
8. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999 : 2 : 91 104.
9. Koch AE, Kunkel SL, Pearce WH et al. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am J Pathol 1993 : 5 : 1423 31.
10. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 2003 : 3 : 834 41.
11. Bach JF. Immunosuppressive therapy of autoimmune diseases. Immunol Today 1993 : 6 : 322 6.
12. Stabler T, Piette JC, Chevalier X, Marini-Portugal A, Kraus VB. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum 2004 : 11 : 3663 7.
13. de Lemos JA, Morrow DA, Sabatine MS et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003 : 5 : 690 5.
14. Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 1999 : 1 : 32 41.
15. Tavill AS. American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology 2001 : 33 : 1321 8.
16. Dooley J, Worwood M. Guidelines on diagnosis and therapy - genetic haemochromatosis. Br Comm Stand Haematol 2000 : 1 33.
17. Molloy RM, Mc Connell RI, Lamont JV, FitzGerald SP. Automation of biochip array technology for quality results. Clin Chem Lab Med 2005 : 12 : 1303 13.
18. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005 : 7 : 1165 76.
19. Berrahmoune H, Lamont JV, Herbeth B, Fitzgerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clin Chem 2006 : 3 : 504 10.
20. Jeffrey GP, Chakrabarti S, Hegele RA, Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet 1999 : 22 : 325 6.
21. Merryweather-Clarke AT, Pointon J, Shearman J, Robson K. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997 : 43 : 275 8.
22. Siedel J, Wahlefeld AW, Ziegenhorn J. A new iron ferrozine reagent without deproteinization. Clin Chem 1984 : 30 : 975.
23. Murtagh LJ, Whiley M, Wilson S, Tran H, Bassett ML. Unsaturated iron binding capacity and transferrin saturation are equally reliable in detection of HFE hemochromatosis. Am J Gastroenterol 2002 : 97 : 2093 9.
24. Mainous AG, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. Ann Fam Med 2004 : 2 : 133 8.
25. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 2002 : 64 : 663 80.
26. Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O, Morrison KE. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005 : 6 : 934 7.
27. Wang XS, Lee S, Simmons Z et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 2004 : 1 : 27 33.
28. Henkel JS, Beers DR, Siklos L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci 2006 : 3 : 427 37.
29. Henkel JS, Engelhardt JI, Siklos L et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004 : 2 : 221 35.
30. Li J, Zhu Y, Singal DP. HFE gene mutations in patients with rheumatoid arthritis. J Rheumatol 2000 : 9 : 2074 7.
31. Cauza E, Hanusch-Enserer U, Etemad M et al. HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis. Clin Exp Rheumatol 2005 : 1 : 7 12.
32. Pierer M, Rethage J, Seibl R et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by toll-like receptor 2 ligands. J Immunol 2004 : 2 : 1256 65.
33. Wyss-Coray T, Loike JD, Brionne TC et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003 : 4 : 453 7.
34. Combarros O, Garcia-Roman M, Fontalba A et al. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord 2003 : 3 : 151 4.
35. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM. Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 2004 : 4 : 465 74.
36. Candore G, Licastro F, Chiappelli M et al. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 2003 : 4 : 525 8.
37. Gerszten RE, Garcia-Zepeda EA, Lim YC et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999 : 6729 : 718 23.
38. Moalem S, Percy ME, Andrews DF et al. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000 : 1 : 58 66.
39. Pulliam JF, Jennings CD, Kryscio RJ et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 2003 : 1 : 48 53.
40. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001 : 11 : 6483 90.
41. Dehqanzada ZA, Storrer CE, Hueman MT et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006 : 2 : 478 86.
42. Cardoso CS, Araujo HC, Cruz E et al. Haemochromatosis gene (HFE) mutations in viral-associated neoplasia: linkage to cervical cancer. Biochem Biophys Res Commun 2006 : 1 : 232 8.
43. Hofer H, Osterreicher C, Jessner W et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004 : 6 : 1018 22.
44. Fabio G, Zarantonello M, Mocellin C et al. Peripheral lymphocytes and intracellular cytokines in C282Y homozygous hemochromatosis patients. J Hepatol 2002 : 6 : 753 61.
45. Porto G, Vicente C, Teixeira MA et al. Relative impact of HLA phenotype and CD4-CD8 ratios on the clinical expression of hemochromatosis. Hepatology 1997 : 25 : 397 402.
46. Cruz E, Melo G, Lacerda R, Almeida S, Porto G. The CD8+ T-lymphocyte profile as a modifier of iron overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y homozygous subjects. Blood Cells Mol Dis 2006 : 37 : 33 9.
47. Lebray P, Zylberberg H, Hue S et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 2004 : 2 : 175 82.